These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7206866)

  • 1. [Need for gastric acidification in the treatment of abdominal migraine. Results of a multicenter study on the association of Séglor retard and Vagosérine].
    Med Chir Dig; 1980; 9(6):541-4. PubMed ID: 7206866
    [No Abstract]   [Full Text] [Related]  

  • 2. [Value of gastric acidification by vagoserine in the treatment of gastroesophageal reflux].
    Chevrel B
    Med Chir Dig; 1980; 9(3):265-8. PubMed ID: 7382608
    [No Abstract]   [Full Text] [Related]  

  • 3. [Vagoserine in hyposthenic dyspepsia].
    Viguié R
    Med Chir Dig; 1979; 8(6):577-81. PubMed ID: 529859
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
    Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of migraine with retard dihydroergotamine. Results of a multicenter study in 643 patients].
    Wörz R
    Fortschr Med; 1986 Nov; 104(43):838-42. PubMed ID: 3542767
    [No Abstract]   [Full Text] [Related]  

  • 6. [The long term use of dihydroergotamine (DHE-45) in migraine treatment (author's transl)].
    Miyazaki T
    Masui; 1978 Jan; 27(1):79-84. PubMed ID: 633616
    [No Abstract]   [Full Text] [Related]  

  • 7. DHE retard for prophylactic therapy of migraine: efficacy and tolerability.
    Centonze V; Attolini E; Santoiemma L; Brucoli C; Macinagrossa G; Campanozzi F; Albano O
    Cephalalgia; 1983 Aug; 3 Suppl 1():179-84. PubMed ID: 6616601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.
    Pradalier A; Lantéri-Minet M; Géraud G; Allain H; Lucas C; Delgado A
    CNS Drugs; 2004; 18(15):1149-63. PubMed ID: 15581385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of transformed refractory migraine with intravenous dihydroergotamine].
    Cid C; Ortega-Valín F; Valero M; Muñoz R; Pascual J
    Neurologia; 1999; 14(6):315-8. PubMed ID: 10439626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo].
    Hoernecke R; Doenicke A
    Med Klin (Munich); 1993 Nov; 88(11):642-8. PubMed ID: 8295604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Beta-endorphin and dihydroergotamine in migraine. Preliminary study].
    Pradalier A; Kerdelhue B; Dry J
    Therapie; 1984; 39(3):331-2. PubMed ID: 6087492
    [No Abstract]   [Full Text] [Related]  

  • 12. [Migraine therapy with magnesium glutamate].
    Vosgerau H
    Ther Ggw; 1973 Apr; 112(4):640 passim. PubMed ID: 4725298
    [No Abstract]   [Full Text] [Related]  

  • 13. [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
    Pradalier A; Guérard des Lauriers A; Scheck F; Peraudeau P; Lacoste JP; Cajfinger F
    Pathol Biol (Paris); 1995 Nov; 43(9):806-13. PubMed ID: 8746103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in migraine: treatment with dihydroergotamine-retard.
    Mastrosimone F; Iaccarino C
    Cephalalgia; 1983 Aug; 3 Suppl 1():168-70. PubMed ID: 6616599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of status migrainosus after electroconvulsive therapy with dihydroergotamine.
    Stead M; Josephs KA
    Headache; 2005 Apr; 45(4):378-80. PubMed ID: 15836577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of migraine attacks in children with dihydroergotamine Spofa and lysenyl].
    Vajnorský J
    Cesk Pediatr; 1986 Nov; 41(11):644-7. PubMed ID: 3814243
    [No Abstract]   [Full Text] [Related]  

  • 17. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
    Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC
    Headache; 2007 Jun; 47(6):878-85. PubMed ID: 17578539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroergotamine: role in the treatment of migraine.
    Schürks M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new therapeutic approach to menstrual migraine].
    Rozenbaum H
    Rev Fr Gynecol Obstet; 1984; 79(7-9):581-3. PubMed ID: 6528179
    [No Abstract]   [Full Text] [Related]  

  • 20. Dysphonia associated with carotidynia and migraine responding to dihydroergotamine.
    White JR; Bell WL
    Headache; 2003 Jan; 43(1):69-71. PubMed ID: 12864762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.